Daiichi Sankyo’s cancer drug wins the FDA’s coveted ‘breakthrough’ tag

Damian Garde

Sankyo picked up the FDA's breakthrough therapy designation for a Phase III , putting it in line for preferential access to agency experts as it moves toward approval.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS